Kodiak Sciences Aces Second Phase 3 Trial for Zenkuda in Diabetic Retinopathy
NEW YORK, April 2 -
Kodiak Sciences (KOD) now has two positive Phase 3 trials for Zenkuda in diabetic retinopathy. The stock is up 19% since the readout.
- GLOW2 primary endpoint: 62.5% of Zenkuda patients achieved a ≥2-step improvement in diabetic retinopathy severity vs 3.3% on sham (p<0.0001)
- Market cap sits around $2.3bn. a fraction of the $15bn retinal disease market Kodiak wants a piece of
- Next catalyst: BLA filing timeline and detailed GLOW2 data at an upcoming medical conference
What Actually Happened
Zenkuda (tarcocimab tedromer) crushed the GLOW2 primary endpoint. The secondary endpoints weren't close either. an 85% risk reduction in sight-threatening complications (2.4% vs 15.8%, p=0.0001). This is the second registrational trial to hit, after GLOW1. Kodiak now has the two pivotal studies the FDA typically requires before accepting a Biologics License Application.
The drug is an anti-VEGF antibody built on Kodiak's ABC platform, designed to last six months between injections. a standard intravitreal shot, not a surgical implant. That dosing interval is the commercial case. Patients hate eye injections. Twice a year instead of monthly is a concrete advantage over Regeneron's Eylea.
One detail worth flagging: Zenkuda's efficacy held regardless of whether patients were on GLP-1 drugs (60.0% response with GLP-1s vs 64.3% without). A persistent bear thesis on retinal drugs has been that Ozempic and its cousins might reduce diabetic retinopathy enough to shrink the addressable market. Kodiak just showed its drug works either way.
The Catch
Both GLOW trials were sham-controlled. Beating a placebo is necessary but not sufficient. retina doctors already have Eylea and Roche's Vabysmo in their toolkit. Until Kodiak shows head-to-head data against an active comparator, the durability advantage is a selling point on paper, not in practice. This is also a company that knows failure: tarcocimab previously flopped in a wet AMD non-inferiority trial against aflibercept, sending KOD from $100+ to under $2. The 52-week low of $1.92 tells you how close this story came to ending. Kodiak still has no revenue and burns cash. EPS was -$4.12 over the trailing twelve months.
Bottom Line
Two clean Phase 3 wins change the risk profile. Kodiak moves from clinical-stage gamble to probable FDA filer. a real shift for a $2.3bn market cap company targeting a multi-billion-dollar indication. But the stock already reflects much of that optimism after the 19% move. The key date is the BLA filing. If Kodiak submits in 2026, a potential 2027 approval and commercial launch follow. into a market where six-month dosing could take share from entrenched competitors.
We don't have a full Basis Report on Kodiak Sciences yet. Generate your KOD report here to get the complete financial picture.
Basis Report does not hold positions in securities discussed. This is not investment advice.